SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Conflicting reports around Nvidia's 18A chip engagement are central to Intel's trending discussion, with many dismissing negative news as FUD and a "hit piece." The community expresses strong conviction in Intel's foundry turnaround, buoyed by US antitrust clearance for Nvidia's substantial investment and a significant partnership with the Department of Energy for AI scientific discovery. This optimism prevails despite perceived market manipulation and frustration over recent price action.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

OMER is trending on high anticipation for an imminent FDA approval decision for its drug Narsoplimab, targeting a deadly disease with no approved treatments. The community is buzzing with speculation around a potential "Christmas miracle" approval, fueled by the company's recent strategic partnership with Novo Nordisk and strong clinical data, anticipating a significant short squeeze and a re-rating of the stock's value despite past regulatory hurdles.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following the successful launch of its BlueBird-6 satellite, a key milestone toward direct-to-device cellular broadband for standard smartphones. The community is buzzing with excitement over this validation of their next-generation technology, anticipating long-term bullish momentum as the company progresses toward commercial scalability. While many celebrate, some investors are also discussing potential short-term profit-taking given the recent run-up and holiday trading conditions.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as it prepares for inclusion in the S&P MidCap 400 index, a development expected to enhance its institutional visibility and liquidity. The community is actively discussing the potential for increased buying pressure from index funds and sees this as a significant validation. Many are also comparing UiPath to other rapidly growing AI stocks, recognizing its leadership in the Agentic AI and automation space.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending amidst intense shareholder frustration over leadership's perceived inaction on securing a major partnership for its differentiated non-mRNA vaccine assets, particularly following a competitor's recent acquisition at a substantial premium. The community is buzzing with speculation that an anticipated 'black box' warning for mRNA vaccines could significantly re-evaluate Novavax's market position, alongside ongoing pressure for a strategic buyout from activist investors.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax Technologies is trending significantly due to an agreement for its acquisition by Sanofi through a cash buyout offer. This news is driving widespread community discussion, with many long-term investors expressing both relief and some frustration over the valuation after years of minimal stock appreciation, as Sanofi aims to enhance its adult immunization portfolio with Dynavax's vaccine assets and adjuvant technology.

Starfighters Space Inc

Starfighters Space Inc. ($FJET), a recent IPO in the aerospace sector, is experiencing extreme volatility, rocketing higher after its debut and subsequently plummeting. The community is sharply divided, with bulls anticipating a massive short squeeze and further "Mach 2" ascent due to its low float, while bears label it an overvalued "pump and dump" with questionable fundamentals and high dilution risk. This has created a highly speculative trading environment, with many discussing its potential as a meme stock versus a rapid decline.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending amid starkly divided community sentiment, with many holders expressing frustration over current price levels and labeling it a "scam" or "dead" project. However, a passionate segment of the community remains highly confident, viewing this period as a key accumulation opportunity and anticipating a significant rally. This intense polarization and active debate around its future are driving conversations.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

AVNT is a trending crypto asset, heavily discussed for its recent listing on Robinhood and its role as a decentralized perpetual exchange built on Coinbase's #base app, targeting the Real-World Asset (RWA) sector. The community is actively debating its potential to outperform competitors like $ASTER and $HYPE, though sentiment is split between bullish optimism for upcoming developments and strong skepticism from those concerned about recent price volatility and perceived issues with token unlocks and buybacks.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X is experiencing heightened interest as market commentary highlights its advanced quantum sensing and timing solutions for national security applications. The community is actively discussing Infleqtion's (the merger target) commercially viable technology and strategic partnerships, positioning it favorably against other quantum sector peers. Many anticipate a significant re-rating and institutional investment once the impending merger is completed.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Top Pharmaceutical Stocks To Add to Your Watchlist - November 6th

Eli Lilly and Company, Pfizer, Novo Nordisk A/S, 89BIO, McKesson, AbbVie, and Teva Pharmaceutical Industries are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock...

RHHBY's Sales Up 7% in First 9 Months of 2025, '25 Earnings View Raised 

Roche's Q3 sales climbed 6% to CHF 14.9B, powered by surging demand for Phesgo, Xolair, Hemlibra, Vabysmo, and Ocrevus.

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of Shareholders

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of Shareholders SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of...

Roche Wins FDA Nod for Label Expansion of Tecentriq in Lung Cancer

Roche gains FDA approval for Tecentriqs expanded label, marking the first combo maintenance therapy for extensive-stage small cell lung cancer. 

Shares of Viking Therapeutics rose 3.4% to $26.25 on Monday and extended gains after hours,&nbsp;with a Wall Street research firm suggesting the biopharma is benefiting from Pfizer’s buyout offer for Metsera as it looks to bolster its obesity drug pipeline.BTIG reiterated a ‘Buy’ rating and $125 price target on&nbsp;Viking’s stock, saying the transaction sharpens&nbsp;the company’s&nbsp;clinical updates and strategic optionality while bolstering sentiment ahead of key readouts. The commentary followed&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/89bio-stock-surges-roche-3-5b-buyout-wall-street-analyst-cautious/chDdNVaR3br">Roche’s acquisition of 89bio</a>, signaling increased deal activity in the biotech space.Meanwhile,&nbsp;<a href="https://stocktwits.com/symbol/MTSR">Metsera’s stock</a> surged to an all-time high Monday, marking their biggest one-day gain ever.&nbsp;As part of the deal, Pfizer will pay Metsera $47.50 in cash per share, giving the company an enterprise value of $4.9 billion. If three clinical milestones are achieved, additional payments of $22.50 per Metsera share will be made, bringing the total value of the deal to as much as $7.3 billion. The deal is expected to close in the fourth quarter of 2025, pending approvals.Metsera, a clinical-stage biotech developing therapies for obesity and cardiometabolic diseases, will add four differentiated programs to Pfizer's pipeline. The assets include weekly and monthly injectable GLP-1 receptor agonists, two orally delivered GLP-1 candidates, and MET-233i, a monthly injectable amylin analog. The company previously discontinued its own obesity candidate Danuglipron.Viking was also in the spotlight, with Daniel Newman, CEO of Futurum Equities,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/danielnewmanUV/status/1970178447411683535">posting on X</a> that Viking’s valuation “just got a massive shot in the arm with the Pfizer deal to buy Metsera,” describing Metsera’s GLP-1 program as “a far less exciting GLP” and arguing that Viking is “worth far more than $7.2 billion.”On Stocktwits, retail sentiment was ‘extremely bullish’ for both Pfizer and Metsera amid ‘extremely high’ message volume, while Viking drew ‘bullish’ sentiment alongside ‘high’ activity.One bullish user said Viking management had likely rejected lowball offers from large pharma, leaving rivals to acquire ‘inferior pipelines.<stembedurl>https://stocktwits.com/deerhtide/message/629602680</stembedurl>Another pointed to debate over whether Viking should pursue a buyout or go-it-alone strategy, adding that CEO Brian Lian’s stake of more than two million shares aligns him with investors. The user disclosed holding 83,000 shares, calling the position conviction-driven.<stembedurl>https://stocktwits.com/SauceMan912/message/629604221</stembedurl>So far this year,&nbsp;<a href="https://stocktwits.com/symbol/PFE">Pfizer’s stock</a> is down 4.5%, Metsera’s shares have more than doubled, and&nbsp;<a href="https://stocktwits.com/symbol/VKTX">Viking Therapeutics’ stock</a> has fallen 34.8%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of Viking Therapeutics on July 19, 2025. (Photo illustration by Cheng Xin/Getty Images)

Viking Therapeutics Stock Gets Boost From Pfizer-Metsera Deal, Says BTIG — Retail Slams Rivals For Buying ‘Inferior Pipelines’

BTIG said Pfizer’s $7.3 billion Metsera acquisition sharpens its clinical updates and strategic optionality.

Equity

Wolfe Research’s Andy Chen cut his rating on 89bio to 'Peer Perform' from 'Outperform'&nbsp;and did not assign a price target after the biotech firm agreed to a $3.5 billion takeover by Roche.&nbsp;<a href="https://stocktwits.com/symbol/ETNB">89bio’s stock</a> surged 85% on Thursday to end at $14.96, its best day on record and the highest level in about a year and a half, before easing 0.03% in after-hours trading.<a href="https://stocktwits.com/news-articles/equity/markets/why-did-89bio-stock-nearly-double-in-value/chDcHJIR3bc">Roche is paying $14.50 a share in cash for 89bio</a>, about 79% above where the stock closed on Wednesday. Investors will also get the chance at another $6 a share in cash if certain milestones are met, though those rights won’t be tradable.&nbsp;On a fully diluted basis, the transaction values 89bio at up to $3.5 billion. An affiliate of Roche will launch a tender offer to acquire all outstanding shares, with closing expected in the fourth quarter, subject to customary conditions. Until then, 89bio will continue to operate independently before joining Roche’s pharmaceuticals division.The acquisition brings Roche 89bio’s late-stage drug candidate Pegozafermin, which is being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis. MASH is a progressive liver disease characterized by fat accumulation leading to inflammation and tissue damage.According to Koyfin, 89bio’s stock has an average 12-month analyst price target of $30.8, with estimates ranging from $12 to $55. The company is covered by 10 analysts, with seven ‘Buy’ ratings, two ‘Hold,’ and no ‘Sell.’ The average rating is ‘Buy.’&nbsp;On Stocktwits, retail sentiment around 89bio was described as 'extremely bullish' with 'extremely high' message volume, while sentiment on Roche was 'bullish' with 'normal' activity.One user noted that Roche’s purchase of 89bio could be part of a broader strategic shopping spree, adding that Sarepta Therapeutics might be next, given the two companies’ long-standing partnership. The user also suggested that Amgen or Pfizer could make competing offers and stated that they planned to hold their position and watch developments.<stembedurl>https://stocktwits.com/GaborPiscis/message/629152949</stembedurl>Another user wondered whether Tempest Therapeutics might be a possible target for Roche following the 89bio deal.<stembedurl>https://stocktwits.com/Fandango23/message/629193287</stembedurl>While 89bio’s stock has risen 91% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/RHHBY">Roche’s stock</a> has climbed 21% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

While 89bio’s stock (ETNB) has risen 91% so far in 2025, Roche’s stock (RHHBY) has climbed 21% over the same period. (Photo credit: Getty Images)

89bio Stock Skyrockets After Roche’s $3.5B Buyout Offer: Retail Bullish, But A Wall Street Analyst Is Cautious 

The acquisition brings Roche rights to Pegozafermin, now in late-stage trials for liver disease MASH.

RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline 

Roche is set to acquire 89bio for $3.5B, adding late-stage MASH drug pegozafermin to its cardiovascular, renal, and metabolic pipeline. 

Shares of 89bio, Inc. (ETNB) jumped 86% in the pre-market session on Thursday after the company said that it has entered into a merger agreement to be acquired by Roche (RHHBY) for up to $3.5 billion on a fully diluted basis.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.89bio.com/news-releases/news-release-details/89bio-inc-announces-agreement-be-acquired-roche">stated</a> that Roche will acquire it for $14.50 per share in cash at closing, representing a premium of approximately 79% to the stock’s closing price on Wednesday. 89bio shareholders will also receive a non-tradeable contingent value right to receive up to an aggregate of $6 per share in cash receivable upon the achievement of certain milestones.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ETNB">ETNB stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:573/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_18_at_7_35_04_AM_png_e0cb1a5888.webp" alt="ETNB's Sentiment Meter and Message Volume as of 7:35 a.m. ET on Sept. 18, 2025 | Source: Stocktwits" width="573" height="59"><figcaption>ETNB's Sentiment Meter and Message Volume as of 7:35 a.m. ET on Sept. 18, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user urged investors to buy the stock now.<stembedurl>https://stocktwits.com/FlyingChemist01/message/629085636</stembedurl>Another opined that the buyout represents a broader trend in which good biopharmaceutical firms are being acquired.<stembedurl>https://stocktwits.com/John62/message/629085287</stembedurl>Under the deal, an affiliate of Roche will commence a tender offer to acquire all of 89bio’s outstanding shares.The closing of the transaction is expected to occur in the fourth quarter, subject to the fulfillment of all closing conditions. Until then, 89bio will operate as a separate and independent company. After the closing of the deal, 89bio will join the Roche group as part of its pharmaceuticals division.The deal includes 89bio’s Pegozafermin, currently in late-stage trials for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis. MASH is a progressive disease characterized by the accumulation of fat in the liver, leading to inflammation and tissue damage.ETNB stock is up 3% this year but down approximately 3% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-surge-after-fed-signals-more-rate-cuts-in-2025/chDcuaaR3GC">Dow Futures Surge After Fed Signals Possibility Of More Rate Cuts This Year: META, PLTR, PYPL, GOOGL Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did 89bio Stock Nearly Double In Value Today?

89bio announced that Roche will acquire it for $14.50 per share in cash at closing, representing a premium of approximately 79% to the stock’s closing price on Wednesday.

Citi says SMid biotechs alternative to large caps as it starts coverage

Investing.com -- Citi has expanded its biopharmaceutical research coverage, initiating coverage on seven small- and mid-cap (SMid) biotechnology companies. Citi said SMid biotechs remain an attractive alternative to large-cap pharmaceutical firms, particularly amid healthcare policy uncertainties. Citi initiated coverage with Buy ratings on 89bio (NASDAQ:ETNB), price target $25. Apogee (NASDAQ:APOG), price target $95. Avidity, price target $70, BioNTech (NASDAQ:BNTX), price target $145. Kiniksa, price target $40. Kymera, price target $52

Companies developing therapies for metabolic steatohepatitis (MASH) saw strong gains even as Novo Nordisk (<a class="mention" data-mention="$NVO" data-symbol-id="NVO" href="https://stocktwits.com/symbol/NVO" target="_blank">$NVO</a>) announced that its GLP-1 drug, semaglutide, demonstrated “superior improvement” in treating the liver disease in its phase 3 ESSENCE trial.&nbsp;Shares of Madrigal Pharmaceuticals (<a class="mention" data-mention="$MDGL" data-symbol-id="MDGL" href="https://stocktwits.com/symbol/MDGL" target="_blank">$MDGL</a>), which received FDA approval earlier this year for its MASH drug, Rezdiffra, rose by 18% following the announcement, with 89Bio (<a class="mention" data-mention="$ETNB" data-symbol-id="ETNB" href="https://stocktwits.com/symbol/ETNB" target="_blank">$ETNB</a>) and Akero Therapeutics (<a class="mention" data-mention="$AKRO" data-symbol-id="AKRO" href="https://stocktwits.com/symbol/AKRO" target="_blank">$AKRO</a>) seeing gains of 15% and 4%, respectively.Novo Nordisk’s ESSENCE trial, a 240-week, double-blind study involving 1,200 adults with MASH and moderate to advanced liver fibrosis, achieved its primary endpoints.&nbsp;After 72 weeks, patients receiving a weekly dose of 2.4 mg semaglutide showed significant liver fibrosis improvement without worsening steatohepatitis, as well as steatohepatitis resolution with no worsening of liver fibrosis, compared to those on placebo.&nbsp;"We are very pleased about the ESSENCE clinical trial results and the potential of semaglutide to help people living with MASH. Among people with overweight or obesity, one in three live with MASH. This has a serious impact on their health and represents a significant unmet need," said Martin Holst Lange, Novo’s executive vice president.The FDA has yet to approve GLP-1 drugs for MASH, though several early trials have shown promise in reversing the disease’s initial stages.&nbsp;In March, Madrigal’s Rezdiffra became the first FDA-approved treatment for MASH with moderate to advanced liver scarring.&nbsp;On Thursday, Madrigal reported robust quarterly earnings, driven by Rezdiffra sales, which led to raised price targets and positive analyst notes.&nbsp;Canaccord boosted its target on Madrigal to $394, citing confidence in continued revenue growth, while UBS increased its target to $441, highlighting an “underappreciated opportunity” in MASH and potential validation from Novo’s findings.<figure class="image"><a href="https://stocktwits.com/symbol/MDGL"><img style="aspect-ratio:1314/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/MDGL_sentiment_and_message_volume_Nov_1_69ab9366a3.png" alt="MDGL sentiment and message volume Nov 1.png" width="1314" height="320"></a><figcaption>MDGL sentiment and message volume Nov 1 as of 1:30 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment for MDGL remained ‘extremely bullish’ as of Friday afternoon amid a spike in message volume, with many fixated on Thursday’s strong results.<stembedurl>https://stocktwits.com/GXD_Texas/message/590911195</stembedurl>Some were also penciling in the next resistance levels for the stock that broke out over $300 this week.<stembedurl>https://stocktwits.com/TheProphetOfProfit/message/590910821</stembedurl>Madrigal’s stock has surged over 33% year-to-date, significantly outperforming broader market benchmarks.For updates and corrections, email&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>Read next: <a href="https://stocktwits.com/news-articles/markets/equity/epix-stock-falls-after-drug-trial-fails/cJEYt4ERBm">Essa Pharma Stock Crashes After Lead Drug Candidate Trial Flops: Retail Hopes Fade</a>

On Thursday, Madrigal reported robust quarterly earnings, driven by Rezdiffra sales, which led to raised price targets and positive analyst notes.

Madrigal Pharma Stock Soars Despite Novo Nordisk’s ‘Superior’ MASH Trial Results: Retail Bullish On Earnings Beat

In March, Madrigal’s Rezdiffra became the first FDA-approved treatment for MASH with moderate to advanced liver scarring.

89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.

ETNB
89bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ETNB News

ETNB89bio Inc